Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction

Asakawa, Jumpei; Iguchi, Taro; Tamada, Satoshi; Ninomiya, Norifumi; Kato, Mototsugu; Yamasaki, Takahiro; Nakatani, Tatsuya

doi:10.1111/iju.13500

Cited by 27 publications

(36 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study evaluating the treatment outcomes of indwelling metallic stents for malignant extrinsic ureteric obstruction, we reported a patency rate of 86.0% at 6 months and 60.0% at 1 year among 52 patients (66 ureters) 14. Our current retrospective analysis follows up on these initial findings, demonstrating the possible superiority of metallic stents over polymeric stents for the treatment of MUO.…”

Section: Discussionsupporting

confidence: 51%

“…In patients with metallic stents indwelled, there were a number of cases of bilateral ureteral obstruction due to gastrointestinal cancer, which may have influenced this outcome. We previously reported that the rate of bilateral obstruction was significantly higher than the rate of unilateral obstruction 14. Moreover, metallic stents have an anticipated indwelling period of 1 year compared to 3–6 months for polymeric stents.…”

Section: Discussionmentioning

confidence: 94%

“…In a previous study, we reported the treatment outcomes of metallic stents for extrinsic MUO in a relatively large retrospective cohort of 52 cases (66 ureters) 14. Among this study cohort, the stent patency rate was 86.0% at 6 months and 60.0% at 1 year.…”

Section: Introductionmentioning

confidence: 90%

See 2 more Smart Citations

Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents

Asakawa¹,

Iguchi²,

Tamada³

et al. 2018

CMAR

Self Cite

View full text Add to dashboard Cite

PurposeTo compare treatment outcomes, more specifically patency rate, of polymeric and metallic stents for malignant ureteral obstruction.Patients and methodsBetween August 2007 and September 2017, we retrospectively analyzed the data of 92 patients (126 ureters) having a diagnosis of malignant extrinsic ureteral obstruction treated with indwelling ureteral stents (polymeric and full-length metallic stents). Of these patients, 35 (54 ureters) were treated with polymeric stents and 57 (72 ureters) with a Resonance® metallic stent. The observation period was censored to 1 year. Survival rate in cases of malignant ureteral obstruction was calculated, and the relationship between the causes of ureteral obstruction, the stent type, and the patency rate was evaluated.ResultsThe median observation period was 145 days, with a median survival time of 258 days. The stent patency rate was 70.9% at 1 year, regardless of stent type. Stent occlusion was observed in 20 patients (33 ureters). According to stent type, occlusion of the polymeric and metallic stents was identified in 12 (22%) and 8 (11%) cases, respectively. The clinical features associated with stent failure were assessed. In univariate analysis, the patency rate was significantly better for the metallic stent than for the polymeric stent (1-year patency rate; 78.4%, 61.1%, respectively, HR, 2.15; 95% CI, 1.07–4.33; p=0.031). However, the patency rate among patients with abdominal dissemination, lymph node metastasis, and direct compression by tumor was not significantly different.ConclusionIndwelling ureteral stents, particularly metallic stents, are effective for the treatment of malignant ureteral obstruction.

show abstract

Section: Discussionsupporting

confidence: 51%

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents

Asakawa¹,

Iguchi²,

Tamada³

et al. 2018

CMAR

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, a metallic stent was approved and used clinically for the treatment of ureteral obstruction [ 3 ]. The metallic stent is tough due to its spiral shape and the hard material from which it is constructed, and can therefore be left in place for a longer period.…”

Section: Discussionmentioning

confidence: 99%

“…The condition is usually first treated by the implantation of a single J stent by a retrograde approach; however, the stent is sometimes bent due to anatomic reasons, necessitating nephrostomy. The Resonance® metal stent is a continuous, unfenestrated, all-metal, double-pigtail ureteric stent with no end or side holes [ 3 , 4 ]. We herein report the first case of a patient with ureteral stricture after radial cystectomy with the creation of an ileal conduit who was successfully treated by the insertion of a metal stent with a combined antegrade and retrograde approach.…”

Section: Introductionmentioning

confidence: 99%

The Use of a Metal Stent in the Treatment of Ureteral Stricture in a Patient Who Had Undergone Radical Cystectomy with the Creation of an Ileal Conduit

et al. 2018

View full text Add to dashboard Cite

Approximately 9.2% of patients who undergo radical cystectomy are reported to develop ureteral stricture as a result of both benign and malignant conditions. A metallic stent is a continuous, unfenestrated all-metal double-pigtail ureteric stent with no end or side holes. The patient was a 74-year-old man who underwent radial cystectomy with the creation of an ileal conduit due to advanced bladder cancer 7 years previously. Although he had no radiographic recurrence, he developed bilateral hydronephrosis. We herein report the first case of a patient with ureteral stricture after radial cystectomy with the creation of an ileal conduit who was successfully treated by the insertion of a metal stent by a combined antegrade and retrograde approach.

show abstract

Risk factors in the prediction of long‐term patency of Resonance metallic ureteric stent in malignant ureteric obstruction

Chiu

Lam

et al. 2020

BJUI Compass

View full text Add to dashboard Cite

Objectives: Cancer is the second leading cause of death globally in 2018 with an estimated 9.6 million deaths. The costs of managing malignant ureteric obstruction (MUO) is a significant burden to any healthcare system. However, the management of MUO has long been a challenge for urologists. The standard options of percutaneous nephrostomy or polymer double J stents are fraught with problems. We report a large patient series with long-term follow-up in the use of Resonance metallic ureteric stents to relieve MUO, and identification of risk factors associated with stent failure.

show abstract

Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction

Abstract: Metallic stents are excellent in maintaining patency compared with the conventional stents. Therefore, they can be used as first-line treatment of malignant ureteral obstructions.

Cited by 27 publications

References 22 publications

Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents

Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents

The Use of a Metal Stent in the Treatment of Ureteral Stricture in a Patient Who Had Undergone Radical Cystectomy with the Creation of an Ileal Conduit

Risk factors in the prediction of long‐term patency of Resonance metallic ureteric stent in malignant ureteric obstruction

Contact Info

Product

Resources

About